Institutional investors purchased a net $604.0 thousand shares of RGEN during the quarter ended December 2016 and now own 95.68% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 416.4 Thousand shares of Repligen Corp
DELAWARE MANAGEMENT BUSINESS TRU... Bought 264.7 Thousand shares of Repligen Corp
FISCHER, FRANCIS, TREES & WATTS,... Bought 215.1 Thousand shares of Repligen Corp